Drug Profile
Research programme: peripheral NMDA receptor antagonists - Rottapharm
Alternative Names: CR 3663Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Rottapharm Madaus
- Class Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Osteoarthritis in Italy
- 23 Oct 2014 Early research is ongoing in Italy
- 10 Oct 2014 Rottapharm Madaus has been acquired by Meda